Department of Pathology, Ohio State University, Columbus, OH, USA.
Diagn Pathol. 2024 Feb 22;19(1):38. doi: 10.1186/s13000-024-01453-w.
This review discusses the profound impact of artificial intelligence (AI) on breast cancer (BC) diagnosis and management within the field of pathology. It examines the various applications of AI across diverse aspects of BC pathology, highlighting key findings from multiple studies. Integrating AI into routine pathology practice stands to improve diagnostic accuracy, thereby contributing to reducing avoidable errors. Additionally, AI has excelled in identifying invasive breast tumors and lymph node metastasis through its capacity to process large whole-slide images adeptly. Adaptive sampling techniques and powerful convolutional neural networks mark these achievements. The evaluation of hormonal status, which is imperative for BC treatment choices, has also been enhanced by AI quantitative analysis, aiding interobserver concordance and reliability. Breast cancer grading and mitotic count evaluation also benefit from AI intervention. AI-based frameworks effectively classify breast carcinomas, even for moderately graded cases that traditional methods struggle with. Moreover, AI-assisted mitotic figures quantification surpasses manual counting in precision and sensitivity, fostering improved prognosis. The assessment of tumor-infiltrating lymphocytes in triple-negative breast cancer using AI yields insights into patient survival prognosis. Furthermore, AI-powered predictions of neoadjuvant chemotherapy response demonstrate potential for streamlining treatment strategies. Addressing limitations, such as preanalytical variables, annotation demands, and differentiation challenges, is pivotal for realizing AI's full potential in BC pathology. Despite the existing hurdles, AI's multifaceted contributions to BC pathology hold great promise, providing enhanced accuracy, efficiency, and standardization. Continued research and innovation are crucial for overcoming obstacles and fully harnessing AI's transformative capabilities in breast cancer diagnosis and assessment.
这篇综述讨论了人工智能(AI)在病理学领域对乳腺癌(BC)诊断和管理的深远影响。它检查了 AI 在 BC 病理学各个方面的各种应用,突出了来自多项研究的关键发现。将 AI 整合到常规病理学实践中有望提高诊断准确性,从而有助于减少可避免的错误。此外,AI 通过其处理大张全切片图像的能力,在识别浸润性乳腺癌肿瘤和淋巴结转移方面表现出色。自适应采样技术和强大的卷积神经网络标志着这些成就。AI 定量分析也增强了对激素状态的评估,这对 BC 治疗方案的选择至关重要,有助于提高观察者间的一致性和可靠性。乳腺癌分级和有丝分裂计数评估也受益于 AI 干预。基于 AI 的框架可以有效地对乳腺癌进行分类,即使是传统方法难以处理的中度分级病例也是如此。此外,AI 辅助的有丝分裂计数在精度和灵敏度方面优于手动计数,有助于改善预后。使用 AI 评估三阴性乳腺癌中的肿瘤浸润淋巴细胞可深入了解患者的生存预后。此外,AI 驱动的新辅助化疗反应预测显示出简化治疗策略的潜力。解决预处理变量、注释需求和分化挑战等局限性对于实现 AI 在 BC 病理学中的全部潜力至关重要。尽管存在现有障碍,但 AI 在 BC 病理学中的多方面贡献具有巨大的潜力,提供了更高的准确性、效率和标准化。持续的研究和创新对于克服障碍并充分利用 AI 在乳腺癌诊断和评估中的变革性能力至关重要。